LJ-001 explained

LJ-001 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped viruses. It acts as an inhibitor which blocks viral entry into host cells at a step after virus binding but before virus–cell fusion, and also irreversibly inactivates the virions themselves by generating reactive singlet oxygen molecules which damage the viral membrane. In cell culture tests in vitro, LJ-001 was able to block and disable a wide range of different viruses, including influenza A, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, and HIV.^[1] Unfortunately LJ-001 itself was unsuitable for further development, as it has poor physiological stability and requires light for its antiviral mechanism to operate.^[2] However the discovery of this novel mechanism for blocking virus entry and disabling the virion particles has led to LJ-001 being used as a lead compound to develop a novel family of more effective antiviral drugs with improved properties.^{[3] [4]}

See also

• Brincidofovir
• BCX4430
• Favipiravir
• FGI-103
• FGI-104
• FGI-106

Notes and References

1. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B . 6 . A broad-spectrum antiviral targeting entry of enveloped viruses . Proceedings of the National Academy of Sciences of the United States of America . 107 . 7 . 3157–62 . February 2010 . 20133606 . 2840368 . 10.1073/pnas.0909587107 . 2010PNAS..107.3157W . free .
2. http://defectivebrain.fieldofscience.com/2013/08/microtwjc-part-2-rise-and-fall-of-lj-001.html The Rise and Fall of LJ-001. Memoirs of a Defective Brain, 19 August 2013
3. Vigant F, Lee J, Hollmann A, Tanner LB, Akyol Ataman Z, Yun T, Shui G, Aguilar HC, Zhang D, Meriwether D, Roman-Sosa G, Robinson LR, Juelich TL, Buczkowski H, Chou S, Castanho MA, Wolf MC, Smith JK, Banyard A, Kielian M, Reddy S, Wenk MR, Selke M, Santos NC, Freiberg AN, Jung ME, Lee B . 6 . A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion . PLOS Pathogens . 9 . 4 . e1003297 . 2013 . 23637597 . 3630091 . 10.1371/journal.ppat.1003297 . free .
4. Hollmann A, Castanho MA, Lee B, Santos NC . Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors . The Biochemical Journal . 459 . 1 . 161–70 . April 2014 . 24456301 . 10.1042/BJ20131058 .